Julie Shilane's Archive

Julie joined Light Knowledge Resources in March of 2008 after graduating from Princeton University with her Ph.D. in Chemistry. Her dissertation research involved the development of small molecule chemotherapeutics. She also has a B.S. in Chemistry and Mathematics from Moravian College. At LKR, Julie works on the development of the Beacon websites. With several family members who have battled cancer, she aspires to help patients through her work at The Beacon. Julie's interests include crafts, playing piano, and spending time with her family.

Julie Shilane has written 86 article(s) .

[ by and | Mar 7, 2014 5:04 pm | 8 Comments ]
Revlimid And Secondary Cancers: Melphalan May Be The Culprit

The findings of a recent retrospective study may alleviate some of the concerns patients and physicians have had about Revlimid and the risk of secondary cancers.

The study found that the risk of developing a secondary cancer as a result of treatment with Revlimid occurred mainly when a patient had been treated with oral melphalan at the same time as Revlimid.

Revlimid (lenalidomide) did not appear to be associated with an in­creased risk of secondary cancers when administered together with

Tags: , , , , , ,
Read the full story »
[ by | Mar 1, 2014 5:56 pm | 2 Comments ]
The Top Myeloma Research Of 2013

The year 2013 is likely to be remembered as a very good year when it comes to research related to multiple myeloma.

Previous years have witnessed research shedding new light on existing my­e­lo­ma therapies, as well as additional research about potential new therapies.

But, in the past, most of the important new therapies that were being researched were from existing classes of therapy, making them less likely to offer dramatic im­prove­ments in the treat­ment of the disease.

In 2013, not …

Tags: , , , , , , , , , , , , ,
Read the full story »
[ by | Feb 15, 2014 8:45 am | Comments Off ]
The Top Myeloma Beacon News Articles Of 2013

Each year, The Myeloma Beacon publishes many news articles sum­ma­rizing the latest research findings about multiple myeloma.  As in recent years, 2013 was a year filled with important multiple myeloma-related news.

During 2013, a new drug, Pomalyst, was approved for the treatment of multiple myeloma; researchers presented new findings about other potential new treat­ments; experts learned more about the factors that influence a patient’s prog­no­sis and reported improvements in survival over the past decade; the role of stem cell trans­planta­tion and …

Tags: ,
Read the full story »
[ by | Feb 10, 2014 3:38 pm | 4 Comments ]
Pomalyst-Based Combination Regimens Presented At ASH 2013

At the 2013 annual meeting of the American Society of Hematology (ASH), which took place in December, there were many oral and poster pre­sen­ta­tions about Pomalyst, the newest drug approved in the United States and Europe for the treatment of multiple myeloma.

Many of the presentations were about studies of Pomalyst (poma­lido­mide, Imnovid) and dex­a­meth­a­sone (Decadron) in combination with a third drug, such as Velcade (bortezomib), Kyprolis (car­filz­o­mib), cla­rith­ro­my­cin (Biaxin), cyclo­phos­pha­mide (Cytoxan), …

Tags: , , , , ,
Read the full story »
[ by | Jan 6, 2014 5:22 pm | 5 Comments ]
Additional Analyses Of Pomalyst Plus Low-Dose Dexamethasone Studies Presented At ASH 2013

More than twenty presentations about studies involving Pomalyst were pre­sented at this year’s meeting of the American Society of Hematology (ASH), which took place last month.

Several of these presentations were about the Phase 3 clinical trial that found Pomalyst (pomalidomide, Imnovid) plus low-dose dex­a­meth­a­sone (Decadron) significantly improved overall survival of relapsed and re­frac­to­ry myeloma pa­tients compared to high-dose dex­a­meth­a­sone alone (see related Beacon news).  This is the study that led to the ap­prov­al of pomalidomide …

Tags: , , , , , ,
Read the full story »